Pittenger & Anderson Inc. Has $7.77 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Pittenger & Anderson Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 75,115 shares of the company’s stock after selling 12,713 shares during the period. Pittenger & Anderson Inc.’s holdings in Novo Nordisk A/S were worth $7,771,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. CNB Bank bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $26,000. Pacific Center for Financial Services boosted its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Valued Wealth Advisors LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $28,000. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 100.0% in the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after purchasing an additional 141 shares in the last quarter. Finally, Bell Investment Advisors Inc lifted its stake in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.5 %

Novo Nordisk A/S stock traded up $1.87 during trading hours on Friday, reaching $127.66. 2,210,764 shares of the company’s stock traded hands, compared to its average volume of 4,783,673. The firm has a market capitalization of $572.88 billion, a price-to-earnings ratio of 47.01, a PEG ratio of 2.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm’s 50 day moving average is $126.80 and its 200-day moving average is $111.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. On average, analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on NVO shares. UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.